Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 May 8;13:150. doi: 10.1186/s12967-015-0509-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Yamamoto et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Therapeutic effects of combination therapy with sorafenib and everolimus in PTEN-deficient prostate cancer. PTEN-deficient mice with CNPC and CRPC were treated with sorafenib, everolimus or sorafenib plus everolimus for 4 weeks as described in the materials and methods (n = 8 mice/group). (A) Representative images of GUTs from mice after indicated treatment. Prostate tumors are highlighted in yellow. Scale is represented in mm. Plots of tumor burden assessed by tumor surface area for CPNC (B) and CRPC (C) intervention models. Plots of cellular proliferation rates relative to control mice assessed by the number of Ki67-positive/Ki67-negative cancer cells (D) and the cellular apoptotic rates relative to control mice assessed by the number of TUNEL-positive cells bodies/total negative cancer cells (E). All plot values represent the percent of control expressed as the mean ± s.e., *P < 0.05, **P < 0.001.